| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.002 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.12 | 0.003 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.083 | 0.004 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.091 | 0.004 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.006 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.31 | 0.007 |